Search Advanced

Mathematical Biosciences and Engineering

2013, Volume 10, Issue 1: 167-184. doi: 10.3934/mbe.2013.10.167
Previous Article Next Article
Special Issues

A structural model of the VEGF signalling pathway: Emergence of robustness and redundancy properties

  • 1.
    INRIA, Project-team NUMED, Ecole Normale Supérieure de Lyon, 46 allée d'Italie, 69007 Lyon Cedex 07
  • Received: 01 July 2012 Accepted: 29 June 2018 Published: 01 December 2012

  • MSC : Primary: 92C42, 92C45, 92E20; Secondary: 65L99.

  • The vascular endothelial growth factor (VEGF) is known as one of the main promoter of angiogenesis - the process of blood vessel formation. Angiogenesis has been recognized as a key stage for cancer development and metastasis. In this paper, we propose a structural model of the main molecular pathways involved in the endothelial cells response to VEGF stimuli. The model, built on qualitative information from knowledge databases, is composed of 38 ordinary differential equations with 78 parameters and focuses on the signalling driving endothelial cell proliferation, migration and resistance to apoptosis. Following a VEGF stimulus, the model predicts an increase of proliferation and migration capability, and a decrease in the apoptosis activity. Model simulations and sensitivity analysis highlight the emergence of robustness and redundancy properties of the pathway. If further calibrated and validated, this model could serve as tool to analyse and formulate new hypothesis on th e VEGF signalling cascade and its role in cancer development and treatment.

    Citation: Floriane Lignet, Vincent Calvez, Emmanuel Grenier, Benjamin Ribba. A structural model of the VEGF signalling pathway: Emergence of robustness and redundancy properties[J]. Mathematical Biosciences and Engineering, 2013, 10(1): 167-184. doi: 10.3934/mbe.2013.10.167

    Related Papers:

  • The vascular endothelial growth factor (VEGF) is known as one of the main promoter of angiogenesis - the process of blood vessel formation. Angiogenesis has been recognized as a key stage for cancer development and metastasis. In this paper, we propose a structural model of the main molecular pathways involved in the endothelial cells response to VEGF stimuli. The model, built on qualitative information from knowledge databases, is composed of 38 ordinary differential equations with 78 parameters and focuses on the signalling driving endothelial cell proliferation, migration and resistance to apoptosis. Following a VEGF stimulus, the model predicts an increase of proliferation and migration capability, and a decrease in the apoptosis activity. Model simulations and sensitivity analysis highlight the emergence of robustness and redundancy properties of the pathway. If further calibrated and validated, this model could serve as tool to analyse and formulate new hypothesis on th e VEGF signalling cascade and its role in cancer development and treatment.


    加载中
    [1] Multiscale Modeling and Simulation, 3 (2005), 440-475.
    [2] Journal of The Royal Society Interface, 4 (2007), 283-304.
    [3] Nature Cell Biology, 8 (2006), 1195-1203.
    [4] Nature Biotechnology, 24 (2006), 667-672.
    [5] Bulletin of Mathematical Biology, 60 (1998), 857-899.
    [6] Bulletin of Mathematical Biology, 66 (2004) 1039-1091.
    [7] Science, 283 (1999), 381-387.
    [8] Journal of Theoretical Biology, 241 (2006), 903-918.
    [9] Journal of Theoretical Biology, 260 (2009), 545-562.
    [10] Progress in Biophysics and Molecular Biology, 97 (2008), 28-39.
    [11] Mathematical Biosciences, 130 (1995), 151-181.
    [12] Nature, 407 (2000), 249-257.
    [13] Cellular and Molecular Life Sciences, 63 (2006), 601-615.
    [14] Nature Reviews Molecular Cell Biology, 7 (2006), 505-516.
    [15] Trends in Biochemical Sciences, 28 (2003), 488-494.
    [16] Oncogene, 30 (2010), 1631-1642.
    [17] Nature Reviews Drug Discovery, 6 (2007), 734-745.
    [18] Nature Reviews Cancer, 2 (2002), 795-803.
    [19] Endocrine Reviews, 25 (2004), 581-611.
    [20] Biochemical and Biophysical Research Communications, 333 (2005), 326-335.
    [21] Cancer Research, 34 (1974), 2109.
    [22] European Journal of Cancer (Oxford, England: 1990), 32 (1996), 2534.
    [23] Microcirculation, 15 (2008), 715-738.
    [24] Journal of Clinical Oncology, 23 (2005), 1295-1311.
    [25] Journal of Biological Chemistry, 273 (1998), 30336-30343.
    [26] Physical Review Letters, 69 (1992), 2013-2016.
    [27] Biochemical Journal, 373 (2003), 451-463.
    [28] Biotechnology Progress, 24 (2008), 96-109.
    [29] Proceedings of the National Academy of Sciences, 93 (1996), 10078-10083.
    [30] Journal of Cell Science, 117 (2004), 4619-4628.
    [31] Nature Medicine, 7 (2001), 987-989.
    [32] Science, 307 (2005), 58-62.
    [33] Nature, 420 (2002), 206-210.
    [34] Nature, 426 (2003), 125-125.
    [35] Nature Biotechnology, 23 (2005), 961-966.
    [36] Physics in Medicine and Biology, 52 (2007), 3665-3677.
    [37] Journal of Biological Chemistry, 274 (1999), 30169-30181.
    [38] European Journal of Biochemistry, 267 (2001), 1583-1588.
    [39] Circulation Research, 100 (2007), 782-794.
    [40] Physical Review Letters, 96 (2006), 58104.
    [41] Molecular Cancer Therapeutics, 7 (2008), 3670-3684.
    [42] Journal of Mathematical Biology, 49 (2004), 111-187.
    [43] Clinical Cancer Research, 9 (2003), 327-337.
    [44] Blood (2012), 5599-5607.
    [45] Endocrine-related cancer, 16 (2009), 675-702.
    [46] Nature Biotechnology, 23 (2005), 1509-1515.
    [47] Nat. Rev. Mol. Cell. Biol., 7 (2006), 357-371.
    [48] International Journal of Radiation Oncology, Biology, Physics, 59 (2004), 928-942.
    [49] Experimental Eye Research, 83 (2006), 1005-1016.
    [50] Journal of Theoretical Biology, 243 (2006), 532-541.
    [51] IET Systems Biology, 3 (2009), 180-190.
    [52] Theoretical Biology and Medical Modelling, 3 (2006).
    [53] Expert review of anticancer therapy, 6 (2006), 1361-1376.
    [54] Nature biotechnology, 20 (2002), 370-375.
    [55] Progress in Biophysics and Molecular Biology, 106 (2011), 450-462.
    [56] The Oncologist, 12 (2007), 465-477.
    [57] Journal of biochemistry and molecular biology, 39 (2006), 469-478.
    [58] Experimental cell research, 312 (2006), 549-560.
    [59] Cancer Research, 64 (2004), 1094-1101.
    [60] Clinical Science, 109 (2005), 227-241.
    [61] Cancer research, 64 (2004), 3731-3736.
    [62] Cancer Research, 35 (1975), 2619-2630.
    [63] Nature Reviews. Cancer, 2 (2002), 489-501.
    [64] Theoretical Biology and Medical Modelling, 4 (2007), 50.
    [65] Frontiers in Computational Physiology And Medicine, 2 (2011) .
    [66] Journal of Theoretical Biology, 250 (2008), 257-280.
    [67] Nature medicine, 10 (2004), 145-147.
    [68] Cancer Cell, 6 (2004), 553-563.
    [69] Bulletin of mathematical biology, 67 (2005), 211-259.
  • Reader Comments
  • © 2013 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Mathematical Biosciences and Engineering
4.4

Metrics

Article views(3891) PDF downloads(642) Cited by(3)

Preview PDF
Download XML
Export Citation
Article outline

Other Articles By Authors

Related pages

Tools

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog